
Rozanolixizumab improved FIQR score at 10 weeks but did not reach 2-sided statistical significance on its primary BPI-SF interference endpoint.
A key opinion leader explore effective non-pharmacological therapies and lifestyle modifications that have shown significant promise in managing fibromyalgia symptoms, complementing traditional medication-based approaches.
Video content above is prompted by the following: